Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AxoGen (AXGN)
NASDAQ:AXGN
AXGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.55 - $19.18
Previous CloseN/A
Volume66.42K
Average Volume (3M)446.18K
Market Cap
$814.15M
Enterprise Value$653.56M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Feb 25, 2025EPS Estimate
0.04Last Dividend Ex-Date
Jan 27, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding44,008,260
10 Day Avg. Volume314,978
30 Day Avg. Volume446,181
Standard Deviation0.19
R-Squared0.08
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.55
Price to Cash Flow (P/CF)52.70
P/FCF Ratio74.40
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.11
Enterprise Value/Ebitda638.87
Forecast
1Y Price Target
$20.00Price Target Upside8.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
AxoGen News
PremiumCompany Announcements
Axogen Reports Strong Revenue Growth and Market Expansion
PremiumCompany Announcements
Axogen Reports Strong Q3 Growth and FDA Progress
---
Bulls Say, Bears Say
Bulls Say
EarningsAXGN pre-announced 4Q24 revenue approximately 4% above consensus, which should quell investor concerns over the implied down quarter-over-quarter guidance.
Growth StrategyAxoGen has truly differentiated products for nerve protection and repair, facing limited biologic competition, which presents ample growth opportunities.
Regulatory ApprovalFDA approval of Avance in 2025 is considered less risky after the agency accepted the BLA submission.
Bears Say
Guidance PerceptionThe management's reiteration of full-year guidance was seen as overly conservative, contributing to an unwarranted sell-off.
Investor SentimentAXGN shares fell significantly, attributed to maintaining FY24 revenue guidance despite a topline beat.
Regulatory ChallengesThe FDA did not grant AXGN's request for priority review, resulting in a later decision date.
---
Ownership Overview
5.32% Insiders
17.37% Mutual Funds
40.01% Other Institutional Investors
23.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $5.55 and its highest was $19.18 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $814.15M.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Feb 25, 2025 which is in 3 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Nov 07, 2024. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.006 by $0.064.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.04.
How many shares outstanding does AxoGen have?
AxoGen has 44,008,260 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.07 in its last earnings report, beating expectations of $0.006. Following the earnings report the stock price went down -13.438%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
---
AxoGen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (8.11% Upside)
$20.00 (8.11% Upside)
Blogger Sentiment
Bullish
AXGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 31.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.0%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.54%
12-Months-Change
Fundamentals
Return on Equity
-14.51%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
---
AXGN Company Deck
---
AXGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth and strategic advancements, particularly with the BLA submission and FDA acceptance. However, challenges remain with a decrease in gross margin and continued net losses.Read More>---
AXGN Stock 12 Month Forecast
Average Price Target
$20.00
▲(8.11% Upside)
Technical Analysis
Baxter International
―
Integra Lifesciences
―
Smith & Nephew Snats
―
Stryker
―
Zimmer Biomet Holdings
―
Best Analysts Covering AXGN
1 Year
1 Year Success Rate
12/23 ratings generated profit
1 Year Average Return
+34.69%
reiterated a buy rating 4 months ago
Copying David Turkaly's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +34.69% per trade.
---